NAFLD is treated by Vitamin D, Omega-3, Curcumin, Silymarinm, etc. Aug 2018

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.

Nutrients. 2018 Aug 23;10(9). pii: E1153. doi: 10.3390/nu10091153.
Cicero AFG1, Colletti A2, Bellentani S3.

 Download the PDF from Vitamin D Life

Non-alcoholic fatty liver disease (NAFLD) is a clinical condition characterized by lipid infiltration of the liver, highly prevalent in the general population affecting 25% of adults, with a doubled prevalence in diabetic and obese patients. Almost 1/3 of NAFLD evolves in Non-Alcoholic SteatoHepatitis (NASH), and this can lead to fibrosis and cirrhosis of the liver. However, the main causes of mortality of patients with NAFLD are cardiovascular diseases. At present, there are no specific drugs approved on the market for the treatment of NAFLD, and the treatment is essentially based on optimization of lifestyle. However, some nutraceuticals could contribute to the improvement of lipid infiltration of the liver and of the related anthropometric, haemodynamic, and/or biochemical parameters. The aim of this paper is to review the available clinical data on the effect of nutraceuticals on NAFLD and NAFLD-related parameters. Relatively few nutraceutical molecules have been adequately studied for their effects on NAFLD. Among these, we have analysed in detail the effects of silymarin, vitamin E, vitamin D, polyunsaturated fatty acids of the omega-3 series, astaxanthin, coenzyme Q10, berberine, curcumin, resveratrol, extracts of Salvia milthiorriza, and probiotics.
In conclusion,

• Silymarin,
• vitamin E and
• vitamin D,
• polyunsaturated fatty acids of the omega-3 series,
• coenzyme Q10,
• berberine and
• curcumin,

if well dosed and administered for medium⁻long periods, and associated to lifestyle changes, could exert positive effects on NAFLD and NAFLD-related parameters.

From PDF

• “NAFLD is an extremely common condition affecting 25–30% of the general adult population, 15% of children, and more than 50% of overweight, obese, and type 2 diabetics.”
• “NAFLD is the first step for the development of irreversible alterations of the liver parenchyma leading to cirrhosis (about 1/3 of the cases of NAFLD tend to become NASH, and 15% of these can degenerate into cirrhosis), while on the other hand, NAFLD is itself a risk factor for the development of cardiovascular disease 10 and type 2 diabetes, and preliminary data suggest that it may also be associated with a greater incidence of hepatic and extra-hepatic oncology pathologies”